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DOES THE SHORT-TERM ADMINISTRATION OF
A BENZODIAZEPINE IMPROVE COMPLIANCE
WITH ANTIDEPRESSANT THERAPY?
Mark TL1, Kevin M2,Torigoe Y2
1Medstat, Washington, DC, USA; 2Pharmacia Corporation,
Peapack, NJ, USA
OBJECTIVES: Several recent clinical guidelines recom-
mend using benzodiazepines as a bridging agent with
antidepressants. Studies show that benzodiazepines may
reduce the initial side effects associated with antidepres-
sants such as jitteriness and therefore increase compli-
ance. The goal of this study is to examine whether
compliance or persistence is higher in patients taking ben-
zodiazepines and antidepressants as compared to those
taking antidepressants alone. METHODS: Data came
from the Medstat Marketscan insurance claims database
which includes claims from several million persons with
private health insurance. Individuals were included if they
met the following inclusion criteria: 18 years of age or
older on January 1, 1999; prescribed an antidepressant
within a 2 year time frame (1999 to 2000); enrolled for
at least 60 days after the ﬁrst date of the ﬁrst antidepres-
sant prescription, and not prescribed an antidepressant
within a baseline period of 60 days. Individuals were
deﬁned as benzodiazepine and antidepressant users if they
had ﬁlled a prescription for benzodiazepines in the 30
days prior or 30 days after the prescription for the anti-
depressants. Individuals were considered as having per-
sistence if they either: had at least 2 prescriptions for an
antidepressant occurring within 60 days of each other, or
had one antidepressant prescription with a greater than a
30-day supply. Multivariate logistic regression analysis
was estimated where persistence was the dependent vari-
able and the controls included age, gender, and diagnosis.
RESULTS: Persons taking benzodiazepines in conjuction
with antidepressants had 1.11 times the odds of having
persistence versus persons taking an antidepressant as a
monotherapy. CONCLUSIONS: Physicians should con-
sider using benzodiazepines to improve compliance with
antidepressant therapy.
PMH12
ASSESSING THE RELATIONSHIP OF
GENERALIZED ANXIETY DISORDER AND
PEPTIC ULCER DISEASE
Kassulke JP, Marks AS, Patel H
Caremark, Inc, Northbrook, IL, USA
OBJECTIVES: To identify through retrospective phar-
macy claims analysis the relationship between generalized
anxiety disorder (GAD) and peptic ulcer disease (PUD).
METHODS: A total of 3.7 million continuously eligible
participants (age 18–64) in Caremark’s pharmacy claims
database were retrospectively analyzed for treatment of
GAD and/or PUD from January 2001 through December
2001. Participants were categorized as having either GAD
or PUD when a pharmacy-targeting algorithm was trig-
gered for respective disease states during the time period.
Multivariate logistic regression analysis was used to
determine the relationship between GAD and PUD, con-
trolling for differences in age, gender and income. Multi-
variate logistic regression analysis was also used to
determine the relationship between GAD and the pres-
ence of chronic conditions, excluding allergic rhinitis.
RESULTS: Participants being treated for GAD were asso-
ciated with an increased risk of being treated for PUD
(OR: 2.18, 95% CI: 2.05–2.33; p < 0.0001). Participants
suffering from chronic conditions were associated with an
increased risk of being treated for GAD (OR: 1.99, 95%
CI: 1.98–2.00; p < 0.0001). Participants being treated for
two or more chronic disease states were associated with
an increased risk of being treated for GAD; 2 chronic con-
ditions (N = 437,637, OR: 2.49, 95% CI: 2.46–2.51; p
< 0.0001); 3 chronic conditions (N = 126,624,odds ratio
4.06, 95% CI = 4.00–4.13, p < 0.0001); 4 or more
chronic conditions (N = 34,411, OR: 6.30, 95% CI:
6.14–6.48, p < 0.0001). CONCLUSION: The relation-
ship between GAD and PUD is consistent with previously
published ﬁndings (Goodwin et al. 2002). However, addi-
tional analysis presented here shows that the presence of
two or more chronic condition increases the risk for
GAD. Therefore, the correlation initially identiﬁed
between GAD and PUD may be indicative of the presence
of an underlying chronic condition causing an anxiety
disorder. This evidence suggests that GAD should be con-
sidered as a comorbidity of chronic disease and should be
incorporated into management strategies.
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POLYPHARMACOTHERAPY OF INPATIENTS
WITH SCHIZOPHRENIA
Zhao Z1, Wang PF2, Gutierrez B2, Gaylord B2
1Eli Lilly and Company, Indianapolis, IN, USA; 2Premier, Inc,
Charlotte, NC, USA
OBJECTIVE: To examine recent pharmacologic treat-
ment patterns for hospitalized schizophrenia patients.
METHODS: Premier’s PerspectiveTM database, the
largest U.S. hospital drug utilization database, was used
to identify hospitalized schizophrenia patients discharged
between January 1999 and September 2001. Treatment
regimens for ﬁve classes of psychotropics were analyzed.
Regressions examined relationships between polyphar-
macy patterns and diagnoses, illness severity, and patient
and institution characteristics. RESULTS: Of 42,233
patients (55% male, mean age 42 years), 94.9% received
antipsychotics; 74.4% atypicals, most commonly olanza-
pine (46.5%). Mood stabilizers were used by 40.9% 
of patients, antidepressants by 47.6%, anxiolytics by
66.8%, and hypnotics by 23.4%. Only 7.9% of patients
received monotherapy. On average, patients received 3.67
psychotropics; 74.2% received 3 and 27.4% received 5
psychotropics. Most common regimens were antipsy-
chotic and anxiolytic combinations (13.6%); this combi-
